8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Mar 20, 2026·SEC
Material company update
Mar 9, 2026·SEC
Relmada Therapeutics, Inc.(RLMD)Earnings, Financials & Key Ratios
RLMD•NASDAQ
$6.69
Price updated Jun 27, 2026
AboutRelmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.Show more
- Revenue$0
- EBITDA-$59M+29.6%
- Net Income-$57M+28.3%
- EPS (Diluted)-1.45+45.3%
- ROE-94.05%+28.9%
RLMD Price & Volume
Relmada Therapeutics, Inc. (RLMD) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Threatens Future Operational Viability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Acute liquidity and insolvency
"Relmada Therapeutics remains a high-risk, clinical-stage entity entirely dependent on external capital to fund its RELIANCE-II program, as it currently lacks any commercial revenue streams. The company's reliance on stock-based compensation, which reached $3.2 million in 2025Q4, masks the underlying economic cost of its R&D-heavy business model. Investors should remain cautious as the firm's history of massive retained earnings deficits, totaling $717.3 million, suggests a structural inability to achieve self-sustaining profitability without further dilutive financing."
Verdict Logic
the company's acute liquidity crisis, highlighted by a $15.1 million quarterly free cash flow burn, indicates a high probability of further shareholder dilution to maintain clinical operations.
RLMD Growth Metrics
Relmada Therapeutics, Inc. (RLMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM22.23%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM55.78%
Return on Capital
10 Years-142.33%
5 Years-99.85%
3 Years-108.89%
Last Year-96.02%
RLMD Recent Earnings
Relmada Therapeutics, Inc. (RLMD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.22-22.2%
$0.18
Rev
—
—
Q2 2026
Mar 19, 2026Metric
Actual
Est
EPS
$0.27-92.9%
$0.14
Rev
—
—
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.30-650.0%
$0.04
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.30-20.0%
$0.25
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.22vs $0.18-22.2% | — |
| Q2 2026 | Mar 19, 2026 | $0.27vs $0.14-92.9% | — |
| Q4 2025 | Nov 13, 2025 | $0.30vs $0.04-650.0% | — |
| Q3 2025 | Aug 7, 2025 | $0.30vs $0.25-20.0% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Relmada Therapeutics, Inc. (RLMD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.69 | $490.6M | -4.61 | — | — | -94.05% | — | |
| $241.67 | $12.44B | -65.67 | 65.55% | -26.59% | -260.01% | — | |
| $5.19 | $401.15M | 32.44 | -4.9% | 3.16% | 12.53% | — | |
| $23.57 | $1.74B | 7.14 | 18.52% | 118.91% | 47.59% | — | |
| $327.79 | $9.47B | -24.32 | -100% | — | -43.02% | — | |
| $25.32 | $4.34B | 11.06 | 11.87% | 34.3% | 35.65% | — |
Compare RLMD vs Peers
Relmada Therapeutics, Inc. (RLMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RLMD SEC Filings & Documents
Relmada Therapeutics, Inc. (RLMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when RLMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RLMD Frequently Asked Questions
Relmada Therapeutics, Inc. (RLMD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is RLMD profitable?
Relmada Therapeutics, Inc. (RLMD) reported a net loss of $58.9M for fiscal year 2025.
Dividend & Returns
What is RLMD's return on equity?
Relmada Therapeutics, Inc. (RLMD) has a return on equity (ROE) of -94.0%. Negative ROE indicates the company is unprofitable.
What is Relmada Therapeutics, Inc.'s free cash flow?
Relmada Therapeutics, Inc. (RLMD) had negative free cash flow of $42.8M in fiscal year 2025, likely due to heavy capital investments.